Active Biotech to present at UBS Global Life Sciences Conference
This annual conference is attended by approximately 3,000 investment professionals and pharmaceutical decision-makers.
From Active Biotech will be present; Sven Andréasson CEO and Tomas Leanderson CSO.
The presentation, scheduled to take place on Thursday, September 29 at 03:30-04:00 pm (local time) will include the development of Active Biotech's oral MS drug laquinimod, that is ongoing in partnership with Teva Pharmaceutical Industries Ltd. as well as the novel concept for treatment of lung cancer, ANYARA. It will also include an update of the other key projects in clinical development, TASQ for prostate cancer, 57-57 for Lupus (SLE) and RhuDex® (licensed to Avidex Ltd.) for RA.
For more details about Active Biotech and ongoing projects, please visit our web page www.activebiotech.com
For further information, please contact:
Cecilia Hofvander, Manager Corporate Communication, tel: +46 46-19 11 22
Active Biotech AB
Box 724, SE-220 07 Lund
Tel: +46 46-19 20 00
Fax: +46 46-19 20 50